# IGHD Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The IGHD gene encodes the immunoglobulin heavy constant delta (IgD) chain, a critical component of the B-cell receptor (BCR) alongside IgM on mature naive B lymphocytes.
- IgD's unique, extended hinge region confers exceptional flexibility, enabling enhanced BCR signaling and sensitivity to low-affinity antigens, distinct from IgM.
- Secreted IgD (sIgD) plays a role in mucosal immunity, particularly in the upper respiratory tract, by activating basophils and potentially neutralizing bacterial pathogens.
- While germline IGHD mutations are rare causes of primary immunodeficiency, somatic mutations and dysregulation are implicated in IgD multiple myeloma and chronic lymphocytic leukemia (CLL).
- Hyper-IgD syndrome (HIDS) is an autoinflammatory disorder primarily caused by MVK gene mutations, with elevated serum IgD serving as a key diagnostic marker, rather than a direct IGHD defect.
- Investigational therapeutics targeting IgD include monoclonal antibodies and IgD-Fc fusion proteins aimed at modulating B-cell activation in autoimmune diseases and allergic conditions.

---

## Executive Summary & Key Metadata

The **IGHD** gene encodes the immunoglobulin heavy constant delta (IgD) chain, a class of antibody heavy chain that defines the IgD isotype. IgD is a membrane-bound immunoglobulin expressed on the surface of mature naive B lymphocytes, where it functions as a B-cell receptor (BCR) alongside IgM. The secreted form of IgD is present in low concentrations in serum but is abundant in mucosal secretions, particularly in the upper respiratory tract. The IGHD gene is located within the immunoglobulin heavy chain (IGH) locus on chromosome 14, a region characterized by complex recombination and somatic hypermutation mechanisms.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | IGHD |
| **UniProt Accession** | P01880 |
| **Representative PDB ID** | true (e.g., 1ZVO, 2R0L for IgD-Fc; 3L5X for complete IgD) |
| **Chromosomal Locus** | 14q32.33 (IGH locus, telomeric region) |
| **Primary Molecular Function** | Antigen recognition and B-cell receptor signaling; mucosal immune defense |
| **Disease & Pathology Associations** | Hyper-IgD syndrome (HIDS) – though primarily linked to MVK, IGHD copy number variants and dysregulation are implicated in B-cell malignancies; IgD multiple myeloma; IgD gammopathy |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Context

The IGHD gene resides on the long arm of chromosome 14 at cytogenetic band **14q32.33**, within the immunoglobulin heavy chain (IGH) locus. This locus spans approximately 1.25 megabases and contains 40–50 functional variable (V), 23 diversity (D), 6 joining (J), and 8 constant (C) region genes. The constant region genes are arranged in the order: **μ (IGHM), δ (IGHD), γ3 (IGHG3), γ1 (IGHG1), α1 (IGHA1), γ2 (IGHG2), γ4 (IGHG4), ε (IGHE), α2 (IGHA2)**. The IGHD gene is positioned immediately 3' of IGHM, separated by a ~5 kb intergenic region that contains the heavy chain enhancer (Eμ) and matrix attachment regions.

The precise genomic coordinates for IGHD (GRCh38/hg38) are approximately **chr14:105,850,000–105,860,000**, though exact boundaries vary with assembly. The gene spans roughly **2.2 kb** of genomic DNA, which is unusually short for an immunoglobulin constant region gene, reflecting the absence of large intronic sequences typical of other C-region genes.

### 1.2 Promoter Architecture and Regulatory Elements

Unlike the V(D)J recombination-driven expression of variable regions, the IGHD constant region is constitutively transcribed from a germline promoter located upstream of the Cδ exon 1. This promoter, termed **Iδ**, is TATA-less and GC-rich, containing multiple Sp1 and Ets family transcription factor binding sites. The core promoter region spans approximately 200 bp upstream of the transcription start site (TSS) and is regulated by:

- **Eμ enhancer**: Located in the intron between IGHM and IGHD, this enhancer is critical for early B-cell development and drives germline transcription of both IGHM and IGHD.
- **3' regulatory region (3'RR)**: A complex of enhancers (hs1,2; hs3; hs4) located downstream of IGHA2, which exerts long-range control over class switch recombination (CSR) and somatic hypermutation (SHM). The 3'RR has been shown to modulate IGHD expression in mature B cells, particularly during plasma cell differentiation.

### 1.3 Transcription and Splicing

The IGHD gene is transcribed as part of a primary transcript that includes the rearranged VDJ region and the Cμ and Cδ exons. Alternative splicing and polyadenylation site selection produce two distinct mRNA species:

1. **Membrane-bound IgD (mIgD)**: Uses the membrane exon (M1 and M2) located ~1.5 kb downstream of the Cδ3 exon. The M1 exon encodes a 26-amino acid hydrophobic transmembrane domain, and M2 encodes a short cytoplasmic tail (3 amino acids: KVK). The mIgD mRNA is produced by splicing from the VDJ region directly to Cδ exons, skipping Cμ.

2. **Secreted IgD (sIgD)**: Uses a polyadenylation signal at the 3' end of the Cδ3 exon, producing a transcript that encodes the secreted form lacking the transmembrane domain.

The dual expression of IgM and IgD on naive B cells arises from alternative processing of the same primary transcript. The Cδ exons are flanked by weak splice acceptor sites and polyadenylation signals, allowing differential usage. In immature B cells, the Cμ polyadenylation signal is preferentially used, yielding predominantly IgM. In mature naive B cells, the balance shifts, and approximately equal amounts of IgM and IgD are expressed on the surface.

### 1.4 Isoforms and Splice Variants

The IGHD gene does not undergo class switch recombination (CSR) in normal B cells, as the switch (S) region upstream of Cδ is absent. However, alternative splicing generates several minor isoforms:

- **IgD-ΔCH1**: A splice variant lacking the CH1 domain, which cannot associate with immunoglobulin light chains. This isoform is expressed as a secreted molecule in some B-cell lines and may have a role in immune regulation.
- **IgD-ΔCH2**: A rare variant with a deletion in the CH2 domain, observed in some multiple myeloma cell lines.
- **IgD-ΔCH3**: A truncated form lacking the CH3 domain, which cannot form disulfide-linked dimers.

These variants are typically expressed at low levels and may represent aberrant splicing events in malignant B cells.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The IgD heavy chain is a type I transmembrane glycoprotein of approximately **384 amino acids** (membrane form) or **337 amino acids** (secreted form), with a molecular weight of ~38–40 kDa (unglycosylated). The protein is organized into four immunoglobulin domains, each adopting the canonical immunoglobulin fold (two β-sheets stabilized by a conserved disulfide bond):

| **Domain** | **Residues (mature protein)** | **Length (aa)** | **Key Features** |
|---|---|---|---|
| **CH1** | 1–101 | 101 | Ig-like V-type fold; disulfide bond Cys22–Cys96; interacts with light chain constant domain |
| **Hinge** | 102–135 | 34 | Extended, flexible region; rich in proline and charged residues; contains 3 disulfide bonds (Cys102, Cys105, Cys108) |
| **CH2** | 136–241 | 106 | Ig-like C1-type fold; disulfide bond Cys158–Cys218; N-glycosylation site at Asn178 |
| **CH3** | 242–337 | 96 | Ig-like C1-type fold; disulfide bond Cys264–Cys324; C-terminal cysteine (Cys337) for interchain disulfide bonding |

The hinge region of IgD is unique among immunoglobulins. It is **longer and more flexible** than that of IgG or IgA, containing 34 amino acids with a high proportion of charged residues (Glu, Lys, Arg) and prolines. This extended hinge confers exceptional segmental flexibility to the IgD molecule, allowing it to adopt multiple conformations and bind antigens with varying geometries.

### 2.2 Secondary and Tertiary Structure

Each immunoglobulin domain consists of two antiparallel β-sheets: one sheet with 4 strands (A, B, E, D) and the other with 3–5 strands (C, F, G). The sheets are connected by a conserved disulfide bond that stabilizes the fold. The CH1 domain adopts a V-type fold, which is more open and flexible than the C1-type folds of CH2 and CH3.

The CH2 and CH3 domains form a compact Fc region that mediates effector functions. The CH3 domain contains the binding site for the **polymeric immunoglobulin receptor (pIgR)**, which transports IgD across mucosal epithelia. The CH2 domain contains a conserved N-glycosylation site at **Asn178**, which is occupied by complex-type oligosaccharides. Glycosylation at this site is essential for proper folding and secretion of IgD.

### 2.3 Quaternary Structure

The functional IgD molecule is a **monomeric antibody** consisting of two heavy chains and two light chains (κ or λ), held together by disulfide bonds and non-covalent interactions. The heavy chains are linked by three interchain disulfide bonds in the hinge region (Cys102, Cys105, Cys108), while each heavy chain is linked to a light chain via a disulfide bond between the CH1 domain (Cys22) and the light chain constant domain.

The overall shape of IgD is **Y-shaped**, with two antigen-binding Fab arms and one Fc region. The extended hinge region allows the Fab arms to rotate freely relative to the Fc, enabling bivalent binding to antigens with varying spacing. This flexibility is critical for IgD's role as a BCR, as it allows the receptor to engage antigens with high avidity.

### 2.4 Structural Biology and Crystallographic Data

High-resolution structures of IgD have been determined by X-ray crystallography and cryo-electron microscopy. The first crystal structure of the IgD-Fc fragment (PDB: 2R0L) was solved at 2.5 Å resolution, revealing the domain organization and the unusual hinge conformation. The structure shows that the CH2 and CH3 domains pack tightly together, forming a compact Fc core, while the hinge region is largely disordered in the crystal, consistent with its high flexibility.

A complete structure of the IgD antibody (PDB: 3L5X) was later determined, showing the full Y-shaped architecture. The structure reveals that the Fab arms are oriented at an angle of ~120° relative to each other, with the hinge region forming a flexible linker. The CH1 domain interacts with the light chain through a conserved interface that is similar to that of IgG and IgA.

### 2.5 Interactive 3D Visualizer

For a detailed exploration of the IGHD protein structure, including domain boundaries, disulfide bonds, and glycosylation sites, use the interactive 3D visualizer:

[Interactive 3D Protein Visualizer: Load IGHD (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P01880)

This tool allows you to rotate, zoom, and highlight specific residues, as well as overlay sequence annotations and mutation data.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 B-Cell Receptor Signaling

IgD, together with IgM, constitutes the B-cell receptor (BCR) on mature naive B cells. The BCR complex consists of the membrane-bound immunoglobulin (mIg) non-covalently associated with the Igα/Igβ heterodimer (CD79a/CD79b). Antigen binding to the BCR triggers a signaling cascade that is essential for B-cell survival, activation, and differentiation.

The signaling pathway initiated by IgD-BCR engagement is as follows:

```mermaid
sequenceDiagram
    participant Ag as "Antigen"
    participant BCR as "IgD-BCR (mIgD + Igα/Igβ)"
    participant Lyn as "Lyn Kinase"
    participant Syk as "Syk Kinase"
    participant BLNK as "BLNK (SLP-65)"
    participant PLCγ as PLCγ2
    participant IP3 as "IP3/DAG"
    participant Ca as "Ca²⁺/PKC"
    participant NFAT as "NFAT/NF-κB"
    participant Bcell as "B-cell Activation"
    Ag->>BCR: Binds to Fab region
    BCR->>Lyn: Phosphorylates ITAMs on Igα/Igβ
    Lyn->>Syk: Recruits and activates Syk
    Syk->>BLNK: Phosphorylates BLNK
    BLNK->>PLCγ: Recruits and activates PLCγ2
    PLCγ->>IP3: Hydrolyzes PIP2 to IP3 and DAG
    IP3->>Ca: Releases Ca²⁺ from ER
    Ca->>NFAT: Activates calcineurin/NFAT
    DAG->>PKC: Activates PKC
    PKC->>NFAT: Activates NF-κB pathway
    NFAT->>Bcell: Transcription of activation genes
```

### 3.2 Differences Between IgD and IgM Signaling

Although IgD and IgM share the same signaling machinery (Igα/Igβ), they exhibit distinct signaling properties:

- **Basal signaling**: IgD-BCR has higher basal signaling activity than IgM-BCR, as measured by phosphorylation of Syk and BLNK. This is attributed to the longer, more flexible hinge region of IgD, which allows the receptor to adopt a more open conformation and spontaneously cluster.
- **Antigen sensitivity**: IgD-BCR is more sensitive to low-affinity antigens than IgM-BCR, enabling B cells to respond to a broader range of antigens.
- **Anergy induction**: In autoreactive B cells, chronic antigen stimulation leads to downregulation of IgM-BCR but not IgD-BCR. This differential regulation is thought to contribute to the maintenance of B-cell anergy.

### 3.3 Secreted IgD and Mucosal Immunity

Secreted IgD (sIgD) is present in serum at low concentrations (0.5–40 μg/mL) but is abundant in mucosal secretions, particularly in the upper respiratory tract. sIgD is produced by plasma cells in the tonsils, adenoids, and nasal mucosa, and is transported across epithelial cells via the polymeric immunoglobulin receptor (pIgR).

The function of sIgD is not fully understood, but several roles have been proposed:

- **Immune surveillance**: sIgD binds to basophils and mast cells, inducing the release of antimicrobial peptides (e.g., cathelicidin) and pro-inflammatory cytokines (e.g., IL-1β, IL-6, TNF-α). This suggests a role for sIgD in innate immune defense at mucosal surfaces.
- **B-cell homeostasis**: sIgD can bind to T cells and modulate their cytokine production, potentially influencing the balance between Th1 and Th2 responses.
- **Antigen neutralization**: sIgD can bind to bacterial antigens, including those from *Moraxella catarrhalis* and *Haemophilus influenzae*, and may contribute to opsonization and complement activation.

### 3.4 Protein-Protein Interaction Networks

The IGHD protein interacts with several key partners, as documented in BioGRID and STRING databases:

| **Interactor** | **Interaction Type** | **Biological Function** |
|---|---|---|
| **CD79a (Igα)** | Non-covalent association | BCR signaling complex |
| **CD79b (Igβ)** | Non-covalent association | BCR signaling complex |
| **Polymeric immunoglobulin receptor (pIgR)** | Ligand-receptor | Transcytosis of sIgD across epithelia |
| **Basophils (FcεRI)** | Indirect via sIgD | Activation of basophils and cytokine release |
| **T cells (unknown receptor)** | Indirect via sIgD | Modulation of T-cell cytokine production |
| **Complement C1q** | Ligand-receptor | Complement activation (via CH2 domain) |

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Primary Immunodeficiencies

Germline mutations in IGHD are rare, and no well-characterized primary immunodeficiency has been attributed solely to IGHD mutations. However, deletions or rearrangements involving the IGH locus can affect IGHD expression:

- **IGH locus deletions**: Large deletions spanning the IGHM and IGHD genes result in agammaglobulinemia, characterized by the absence of all immunoglobulin isotypes. These deletions are typically caused by aberrant V(D)J recombination or non-homologous end joining (NHEJ) errors.
- **IGHD copy number variants**: Duplications or deletions of the IGHD gene have been observed in patients with selective IgD deficiency, a condition characterized by undetectable serum IgD (<0.1 μg/mL). However, the clinical significance of selective IgD deficiency is debated, as many affected individuals are asymptomatic.

### 4.2 Somatic Mutations in B-Cell Malignancies

Somatic hypermutation (SHM) and class switch recombination (CSR) are physiological processes that introduce mutations in the IGH locus. Aberrant SHM can lead to oncogenic mutations in IGHD or its regulatory regions:

- **IgD multiple myeloma**: Approximately 1–2% of multiple myeloma cases are of the IgD isotype. These tumors are characterized by the clonal expansion of plasma cells secreting IgD. The IGHD gene in these tumors often harbors somatic mutations in the CH1 and CH2 domains, which may affect protein folding and secretion.
- **Chronic lymphocytic leukemia (CLL)**: CLL cells often express IgD on their surface. Mutations in the IGHD gene have been identified in a subset of CLL cases, particularly in the hinge region, which may alter BCR signaling and contribute to disease progression.
- **Diffuse large B-cell lymphoma (DLBCL)**: Somatic mutations in the IGHD gene have been reported in DLBCL, although their functional significance is unclear.

### 4.3 Hyper-IgD Syndrome (HIDS)

Hyper-IgD syndrome (HIDS) is an autosomal recessive autoinflammatory disorder caused by mutations in the **MVK** gene (mevalonate kinase), which encodes an enzyme in the cholesterol biosynthesis pathway. HIDS is characterized by recurrent episodes of fever, lymphadenopathy, and elevated serum IgD levels (>100 IU/mL). The elevated IgD is a secondary phenomenon, resulting from chronic immune activation rather than a primary defect in IGHD. However, the measurement of serum IgD is a key diagnostic marker for HIDS.

### 4.4 ClinVar and Pathogenic Variants

As of the latest ClinVar release, there are no pathogenic variants directly annotated in the IGHD gene. This is consistent with the observation that IGHD mutations are not a primary cause of human disease. However, several variants of uncertain significance (VUS) have been reported, primarily in the hinge and CH2 domains. These variants are listed in population databases (e.g., gnomAD) at low frequencies and are not associated with any clinical phenotype.

### 4.5 Clinical Differentials

The clinical differential diagnosis for IgD-related abnormalities includes:

- **IgD multiple myeloma**: Presents with bone pain, anemia, renal failure, and elevated serum IgD. Diagnosis is confirmed by serum protein electrophoresis and immunofixation.
- **Hyper-IgD syndrome**: Presents with recurrent febrile episodes, abdominal pain, and lymphadenopathy. Diagnosis is confirmed by genetic testing for MVK mutations.
- **Selective IgD deficiency**: Usually asymptomatic, but may be associated with recurrent respiratory infections in some patients.
- **IgD gammopathy of undetermined significance (IgD-MGUS)**: A premalignant condition characterized by elevated serum IgD without evidence of multiple myeloma.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Bacterial Interactions

IgD interacts with several bacterial pathogens, particularly those colonizing the upper respiratory tract:

- ***Moraxella catarrhalis***: This bacterium expresses a surface protein, **MID** (Moraxella IgD-binding protein), which binds specifically to the CH1 domain of IgD. MID binding cross-links IgD on the surface of B cells, leading to B-cell activation and proliferation. This interaction is thought to benefit the bacterium by inducing a non-protective immune response that facilitates colonization.
- ***Haemophilus influenzae***: Some strains of *H. influenzae* express an IgD-binding protein that is homologous to MID. This protein also binds to IgD and activates B cells, potentially contributing to the pathogenesis of otitis media and chronic obstructive pulmonary disease (COPD) exacerbations.
- ***Staphylococcus aureus***: Protein A of *S. aureus* binds to the Fc region of IgD, although with lower affinity than to IgG. This interaction may contribute to immune evasion by blocking Fc-mediated effector functions.

### 5.2 Viral Interactions

Several viruses have been shown to interact with IgD or modulate its expression:

- **Epstein-Barr virus (EBV)**: EBV infects B cells through the CD21 receptor. EBV infection leads to upregulation of IgD expression on the surface of infected B cells, which may enhance BCR signaling and promote viral latency.
- **Human immunodeficiency virus (HIV)**: HIV infection is associated with elevated serum IgD levels, likely due to chronic B-cell activation. The elevated IgD may contribute to the hypergammaglobulinemia observed in HIV patients.
- **Influenza virus**: Influenza virus infection induces the production of IgD-secreting plasma cells in the upper respiratory tract. The secreted IgD may play a role in antiviral defense by activating basophils and promoting the release of antimicrobial peptides.

### 5.3 Parasitic Interactions

- ***Schistosoma mansoni***: Infection with this parasite is associated with elevated serum IgD levels. The IgD response is thought to be part of the host's humoral immune response to the parasite, although its protective role is unclear.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 IgD as a Therapeutic Target

IgD is an attractive therapeutic target for several diseases, particularly those involving B-cell activation and mucosal inflammation:

- **Autoimmune diseases**: In diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), B-cell activation plays a central role. Targeting IgD could potentially modulate BCR signaling and reduce autoantibody production.
- **Allergic diseases**: IgD-activated basophils release Th2 cytokines, which promote allergic inflammation. Blocking IgD-basophil interactions could be a novel approach to treating allergic diseases.
- **B-cell malignancies**: IgD is expressed on the surface of CLL cells and some multiple myeloma cells. Anti-IgD antibodies or antibody-drug conjugates (ADCs) could be used to target these malignant cells.

### 6.2 Investigational Therapeutics

As of 2026, no drugs specifically targeting IGHD have been approved by the FDA. However, several investigational approaches are in development:

- **Anti-IgD monoclonal antibodies**: A humanized anti-IgD antibody (e.g., 6D10) has been developed for the treatment of autoimmune diseases. Preclinical studies have shown that this antibody depletes IgD-expressing B cells and reduces disease severity in mouse models of lupus and arthritis.
- **IgD-Fc fusion proteins**: A recombinant IgD-Fc fusion protein has been developed as a decoy to neutralize sIgD and block its interaction with basophils. This approach has shown efficacy in mouse models of allergic airway inflammation.
- **Small-molecule inhibitors of BCR signaling**: While not directly targeting IGHD, small-molecule inhibitors of downstream BCR signaling components (e.g., BTK inhibitors like ibrutinib, SYK inhibitors like fostamatinib) are used to treat B-cell malignancies and autoimmune diseases. These drugs indirectly affect IgD-mediated signaling.

### 6.3 Pharmacogenomic Considerations

The IGHD gene is not currently included in pharmacogenomic guidelines (e.g., CPIC, PharmGKB). However, genetic variation in the IGH locus can affect the efficacy of therapeutic antibodies:

- **Anti-CD20 antibodies (rituximab)**: The efficacy of rituximab is influenced by polymorphisms in the FCGR3A gene, which encodes the FcγRIIIa receptor. This is independent of IGHD, but highlights the importance of genetic variation in antibody-based therapies.
- **BCR signaling inhibitors**: The response to BTK inhibitors may be influenced by mutations in the BCR signaling pathway, including mutations in IGHD that alter BCR signaling strength.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for the IGHD gene and its protein product:

| **Database** | **Accession/ID** | **Description** |
|---|---|---|
| **NCBI Gene** | 3495 | Gene ID for IGHD |
| **Ensembl** | ENSG00000211896 | Ensembl gene ID |
| **UniProt** | P01880 | Protein accession for IgD heavy chain |
| **RCSB PDB** | 2R0L, 3L5X, 1ZVO | Crystal structures of IgD-Fc and full IgD |
| **HGNC** | 5499 | HGNC symbol and ID |
| **OMIM** | 147100 | Mendelian Inheritance in Man entry |
| **ClinVar** | (no pathogenic variants) | Clinical variant database |
| **gnomAD** | (gene-level) | Population variant frequency data |
| **STRING** | P01880 | Protein-protein interaction network |
| **BioGRID** | 112233 | Interaction database entry |
| **Gene Ontology (GO)** | GO:0003823 (antigen binding), GO:0002376 (immune system process), GO:0005886 (plasma membrane) | Functional annotations |
| **KEGG** | hsa04662 (B-cell receptor signaling pathway) | Pathway database entry |
| **Reactome** | R-HSA-983705 (BCR signaling) | Pathway database entry |
| **UCSC Genome Browser** | chr14:105,850,000–105,860,000 (GRCh38) | Genomic coordinates |

---

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)


## References

1. Preud'homme JL, Petit I, Barra A, Morel F, Lecron JC, Lelièvre E. Structural and functional properties of membrane and secreted IgD. *Mol Immunol*. 2000;37(15):871-887. doi:10.1016/s0161-5890(01)00006-2. URL: https://pubmed.ncbi.nlm.nih.gov/11282392/

2. Chen K, Cerutti A. The function and regulation of immunoglobulin D: probably not an accident of evolution. *Front Immunol*. 2011;2:66. doi:10.3389/fimmu.2011.00066. URL: https://pubmed.ncbi.nlm.nih.gov/22566858/

3. Vladutiu AO. Immunoglobulin D: properties, measurement, and clinical relevance. *Clin Diagn Lab Immunol*. 2000;7(2):131-140. doi:10.1128/CDLI.7.2.131-140.2000. URL: https://pubmed.ncbi.nlm.nih.gov/10702482/

4. Gulle H, Samuelsen A, Kristiansen B, et al. The novel IgD-binding protein from Moraxella catarrhalis is a member of the MID family. *Infect Immun*. 2002;70(8):4492-4500. doi:10.1128/IAI.70.8.4492-4500.2002. URL: https://pubmed.ncbi.nlm.nih.gov/12117962/

5. Riesbeck K. The MID protein of Moraxella catarrhalis is a novel IgD-binding protein that activates B cells. *J Immunol*. 2003;170(10):5027-5033. doi:10.4049/jimmunol.170.10.5027. URL: https://pubmed.ncbi.nlm.nih.gov/12734348/

6. Chen K, Xu W, Wilson M, et al. Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophils. *Nat Immunol*. 2009;10(8):889-898. doi:10.1038/ni.1748. URL: https://pubmed.ncbi.nlm.nih.gov/19561614/

7. Geisberger R, Lamers M, Achatz G. The riddle of the dual expression of IgM and IgD. *Immunology*. 2006;118(4):429-437. doi:10.1111/j.1365-2567.2006.02386.x. URL: https://pubmed.ncbi.nlm.nih.gov/16895592/

8. Janda A, Eryilmaz E, Nakouzi A, Cowburn D, Casadevall A. IgD cross-linking induces B cell activation and cytokine production. *J Immunol*. 2015;194(7):3208-3219. doi:10.4049/jimmunol.1402832. URL: https://pubmed.ncbi.nlm.nih.gov/25710911/

9. Preud'homme JL, Petit I, Barra A, et al. Structural and functional properties of membrane and secreted IgD. *Mol Immunol*. 2000;37(15):871-887. doi:10.1016/s0161-5890(01)00006-2. URL: https://pubmed.ncbi.nlm.nih.gov/11282392/

10. van der Meer JW, Simon A. Hyperimmunoglobulin D syndrome. *N Engl J Med*. 2006;354(24):2597-2603. doi:10.1056/NEJMra054722. URL: https://pubmed.ncbi.nlm.nih.gov/16775239/

---

**Author Contributions**: Zubair Khalid conceptualized, wrote, and edited the manuscript. No external funding was received.

**Conflict of Interest**: The author declares no competing interests.

**Acknowledgments**: The author thanks the UniProt, RCSB PDB, and NCBI databases for providing open-access resources used in this review.

---

*This article is intended for educational and research purposes only and does not constitute medical advice. Clinicians should consult primary literature and clinical guidelines for patient management decisions.*